Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM1315MO2 | TNBC | Basal B | Methylglyoxal | 13520.184 | uM | 567.6950 | 786.82260 | -0.9992 | -0.9966 | 3.3588 | 0.6425 | 0.9974 | 0.6738 | |||
| MDA-MB-134-VI | HR+ | Luminal | 2-deoxyglucose | 12662.177 | uM | inf | inf | 0.9676 | 0.9676 | 0.0000 | 0.0405 | 0.0000 | 1.7065 | |||
| MCF12A | NM | Basal B | Ibandronate | FDPS | 12365.143 | uM | 172.18210 | 247.57150 | -0.0273 | -0.2106 | 0.9681 | 0.2239 | 0.9728 | 2.3865 | ||
| MDA-MB-175-VII | HR+ | Luminal | Ibandronate | FDPS | 10818.143 | uM | 29.27380 | 68.90020 | -0.8212 | -0.9190 | 1.2186 | 0.6018 | 0.9085 | 0.6263 | ||
| MDA-MB-175-VII | HR+ | Luminal | Ibandronate | FDPS | 10642.143 | uM | 14.68780 | 50.81510 | -0.9195 | -1.0000 | 0.8851 | 0.6829 | 0.8879 | 0.5076 | ||
| Hs 578T | TNBC | Basal B | Torkinib | 15352.211 | uM | 0.09021 | 0.26878 | -0.3566 | -0.4047 | 0.5431 | 0.5802 | 0.9760 | 2.5357 | |||
| 21MT-1 | HER2amp | - | Mebendazole | 13719.174 | uM | 31.97060 | 77.55140 | 0.0875 | -1.0000 | 1.2398 | 0.1610 | 0.8782 | 0.8124 | |||
| HCC2185 | TNBC | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 7846.016 | uM | 6.79370 | 6.48310 | -0.3064 | 0.1043 | 5.0000 | 0.3414 | 0.5784 | 0.3279 | ||
| MCF 10F | NM | - | Ibandronate | FDPS | 12254.143 | uM | 177.1340 | 398.44880 | -0.0080 | -0.3886 | 0.7093 | 0.1825 | 0.9772 | 1.4110 | ||
| AU565 | HER2amp | Luminal | Ibandronate | FDPS | 10880.143 | uM | 190.49250 | 139.95740 | 0.2035 | 0.1860 | 1.5087 | 0.1480 | 0.9763 | 1.6077 | ||
| 21MT-1 | HER2amp | - | Methylglyoxal | 13719.184 | uM | 680.32080 | 999.99990 | -0.9954 | -0.9645 | 2.7899 | 0.6345 | 0.9961 | 0.7600 | |||
| HCC2185 | TNBC | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 7845.016 | uM | 26.42820 | 1.11560 | 0.3882 | 0.2272 | 0.1914 | 0.3503 | 0.5905 | 0.4392 | ||
| HCC3153 | TNBC | Basal A | Mebendazole | 12939.174 | uM | 0.09935 | 0.55943 | -0.8642 | -0.9370 | 0.6109 | 0.7618 | 0.9574 | 0.3466 | |||
| BT-483 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 7801.016 | uM | 22.32320 | 38.86550 | -0.9618 | -1.0000 | 1.9813 | 0.3751 | 0.8751 | 0.4118 | ||
| EFM-192A | HER2amp | Luminal | Torkinib | 15284.211 | uM | 0.00167 | 0.00424 | -0.5970 | -0.4552 | 0.6957 | 1.0349 | 0.9758 | 0.8976 | |||
| HCC3153 | TNBC | Basal A | Mebendazole | 13733.174 | uM | 0.22612 | 8.73650 | -0.5068 | -1.0000 | 0.3006 | 0.5298 | 0.8956 | 0.5093 | |||
| HCC1937 | TNBC | Basal A | CGC-11047 | Polyamine analogue | 10262.034 | uM | 2.42290 | 59.75010 | -0.9033 | -1.0000 | 0.3428 | 0.7559 | 0.9172 | 0.6634 | ||
| SUM225CWN | HER2amp | Basal A | Torkinib | 15403.211 | uM | 0.02304 | 0.20245 | -0.6514 | -0.8008 | 0.4399 | 0.7911 | 0.9881 | 0.7553 | |||
| HCC2185 | TNBC | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 7849.016 | uM | 8.93180 | 7.17820 | -0.0960 | 0.3324 | 5.0000 | 0.2075 | 0.5971 | 0.3419 | ||
| HCC1395 | TNBC | Basal B | Glycyl-H-1152 | ROCK2 | 12084.16 | uM | 12.49510 | 36.59980 | -0.0127 | -0.6415 | 0.7681 | 0.1579 | 0.9673 | 1.1178 | ||
| HCC1395 | TNBC | Basal B | Glycyl-H-1152 | ROCK2 | 12000.169 | uM | 5.15510 | 75.12560 | -0.0066 | -1.0000 | 0.4101 | 0.2688 | 0.9786 | 0.8565 | ||
| HCC1143 | TNBC | Basal A | Torkinib | 15349.211 | uM | 0.00212 | 0.02884 | -0.5325 | -0.6450 | 0.3174 | 0.9231 | 0.9841 | 1.2538 | |||
| HCC38 | TNBC | Basal B | TAPI-0 | TACE/Collagenase | 7468.096 | uM | inf | inf | 0.8558 | 0.8558 | 0.0000 | 0.0572 | 0.4094 | 1.5683 |